REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Ortho-hydroxybenzoic Acid (i.e., Salicyclic Acid) Or Derivative Doai > Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid)Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021395 - Compositions for reducing the incidence of drug induced arrhythmia In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, ... 01/11/07 - 20070010499 - Medicinal compositions containing aspirin A combination of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus. ... 01/04/07 - 20070004687 - Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ll antagonist for stroke prevention This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions, ... 12/21/06 - 20060287284 - Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents preferably selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations. ... 12/14/06 - 20060281718 - Treatment of vr1-antagonist-induced increase in body temperature with an antipyretic agent The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like. ... 12/07/06 - 20060276439 - Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); ... 11/09/06 - 20060252732 - Blood vessel-growth promoter A neo-vascularization promoter containing acetylsalicylic acid or its pharmaceutically acceptable salt as an active ingredient. ... 10/26/06 - 20060241089 - Dipyridamole, acetylsalicylic acid, and angiotensin ii antagonist pharmaceutical compositions A pharmaceutical composition comprising a therapeutically effective amount of: (a) dipyridamole or a pharmaceutically acceptable salt thereof; (b) acetylsalicylic acid; and (c) an angiotensin II antagonist, kits containing these three compounds, and methods for preventing stroke or reducing the risk of stroke or secondary stroke in a patient in need ... 10/26/06 - 20060241088 - Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of ... 09/28/06 - 20060217352 - Method for treating thrombosis This invention relates to a method for treating thrombosis by combined administration of a pitavastatin with aspirin. ... 09/28/06 - 20060217351 - Method for treating cardiovascular diseases A method of treating Cardiovascular Diseases comprising administering of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, prodrug, active metabolite, racemate or enantiomer thereof, in conjunction with coronary and non-coronary intervention procedures is disclosed. ... 08/24/06 - 20060189584 - Pharmaceutical combinations The present invention provides novel pharmaceutical combinations and their use in anti-thrombotic therapy. The combinations comprise a compound of formula (I) or a pharmaceutically acceptable derivative thereof; formula (I), and another anti-thrombotic agent or a pharmaceutically acceptable derivative thereof. ... 08/10/06 - 20060178349 - Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid The present invention is directed to compositions containing a 5-HT1F-specific agonist that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat migraine and headache pain. The invention also includes methods in which these drugs are separately administered to a patient. ... 08/10/06 - 20060178348 - Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid The present invention is directed to compositions containing an anti-inflammatory compound that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat inflammation and pain, especially headache pain. The invention also includes methods in which these drugs are separately administered to a patient. ... 08/10/06 - 20060178347 - Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors The invention relates to methods, compositions, and uses of those compositions for making medicaments, for potentiating the beneficial effects of inhibitors of COX-1, COX-2, and 5-LOX, and reducing adverse effects, by also administering inhibitors of soluble epoxide hydrolase (“sEH”), with or without also administering one or more cis-epoxyeicosantrienoic acids. The ... 08/03/06 - 20060172983 - Functionalized drugs and polymers derived therefrom where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ... 07/27/06 - 20060166947 - Multiple myeloma treatments Provided herein are methods for treating refractory or resistant multiple myeloma in a subject using indole derivatives. ... 06/29/06 - 20060142254 - Antipyretic preparation containing xylitol The invention relates to an antipyretic preparation intended to be administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol. The invention also relates to the ... 06/22/06 - 20060135490 - Targeting mpges-1 as a treatment for inflammation which avoids cardiovascular risk The present invention relates to methods for the treatment of inflammation and pain without increasing cardiovascular risk by administration of an inhibitor of mPGES-1. The invention further is related to identifying inhibitors of mPGES-1 that do not increase cardiovascular risk when administered to an individual. ... 04/20/06 - 20060084635 - Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease A medicament for the amelioration and treatment of vascular disease consisting of aspirin administered in combination with one or more of the vitamins including vitamin A, vitamin B6, vitamin C, vitamin E, and niacin. Alternative embodiments include the administration of aspirin in combination with one or more trace element including ... 04/13/06 - 20060079489 - Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine Stable pharmaceutical compositions of descarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include lactose-free, non-hygroscopic and ... 02/02/06 - 20060025387 - Compositions and methods for the treatment of disorders of the central and peripheral nervous systems The present invention relates to methods and compositions for treating disorders of the central and/or peripheral nervous system by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+—2CT (NKCC) cotransporter. In certain embodiments, the Na+—K+—2Cl− co-transporter is NKCC1. ... 01/12/06 - 20060009424 - Nasaleaze Applicant has an idea that the healing powers of combining available “over the counter” medicines Neomycin, Polymyxin B Sulfates and Bacitracin Zinc first aid antibiotic ointment, and Hidrocortizone anti itch ointment produces a medicine named “Nazalease”. When inserted into the nasal cavity, “Nazalease” is capable of treating unwanted nasal deposits. ... 11/10/05 - 20050250745 - Biomarkers for age-related macular degeneration (amd) Provided are methods of using levels of markers of systemic inflammation, e.g., CRP, to predict a subject's risk of development or progression of Age-Related Macular Degeneration (AMD), and methods of treating, delaying or preventing the development or progression of AMD. ... 10/27/05 - 20050239755 - External preparation for inhibiting keloid formation An external preparation which contains acetylsalicylic acid or its salt as an active ingredient and has an effect of inhibiting keloid and/or hypertrophic scar formation as well as an analgesic and antipruritic effect. ... 10/13/05 - 20050227949 - Compositions and methods for treatment of viral and bacterial infections Compositions and methods are presented that are useful for treatment of viral and/or bacterial infections, and especially the common cold or flu. Particularly preferred combinations include those orally administered, preferably early in the course of the symptoms of the cold or flu, and comprising (a) an H2-histamine receptor antagonist and ... 09/29/05 - 20050215533 - Method to inhibit ischemia and reperfusion injury Methods of treating or inhibiting ischemia and reperfusion injury are provided. ... 08/04/05 - 20050171070 - Stable salts of o-acetylsalicylic acid containing basic amino acids ii The present invention relates to improved compositions comprising stable salts of O-acetylsalicylic acid with basic amino acids, to pharmaceuticals comprising them and to their use for preparing pharmaceuticals. ... 07/21/05 - 20050159395 - Nsaid-containing topical formulations that demonstrate chemopreventive activity Disclosed herein are chemopreventive methods and topical formulations for the prevention and treatment of ultraviolet light-induced skin cancers, pre-cancerous lesions, and hyperproliferative disorders in mammals, such as humans, utilizing doses of non-steroidal anti-inflammatory drugs. Low doses of non-steroidal anti-inflammatory drugs are present in the topical formulations and allow continued regular ... 07/07/05 - 20050148556 - Compositions and methods for increasing hdl and hdl-2b levels The present invention provides compositions and methods for reducing flushing in a patient. In addition, compositions and methods are provided for increasing HDL and/or HDL-2b levels in a patient. In some embodiments, the compositions include an adipocyte G-protein antagonist, a PPAR-α agonist, and a PPAR-γ agonist in amounts effective in ... 07/07/05 - 20050148555 - Methods of treating copd and pulmonary hypertension Disclosed are methods of treating COPD and Pulmonary Hypertension using p38 Map Kinase inhibitors in combination with one or more other active ingredients. ... 06/30/05 - 20050143356 - Selective inhibition of cyclooxygenase 1 in the treatment of diabetic nephropathy The present invention relates to the use of COX-1 selective inhibitors to treat diabetic nephropathy. In particular, COX-1 inhibitors may be combined with standard insulin replacment therapy, and/or combined with ACE inhbitor therapy. The therapy is, in a specific embodiment, designed to inhibit systemic COX-1 activity, reflected by inhibition of ... 06/30/05 - 20050143355 - Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol and methods of using same Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol, and methods of using the same for treating or inhibiting increased urinary urgency or urinary incontinence and/or pain. ... 06/30/05 - 20050143354 - Association of an antithrombotic and aspirin The present invention relates to a new combination of an antithrombotic and aspirin and to pharmaceutical compositions comprising them. ... 06/02/05 - 20050119239 - Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism This invention describes a new combination for the treatment of functional bladder disorders which comprises a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism. ... 06/02/05 - 20050119238 - Compositions and methods for preventing sporadic neoplasia in colon Compositions and methods for preventing sporadic neoplasia of the colon are provided. The compositions provided are be on administration of acetylsalicylic acid. ... ### FreshPatents.com Support |